Antipsychotic use in pregnancy and congenital malformations

Area of Science:

• Pharmacology
• Teratology
• Public Health

Background:

• Antipsychotic medications are frequently prescribed during pregnancy.
• Congenital malformations represent a significant concern for infant health.
• Understanding the risks associated with prenatal drug exposure is crucial for clinical practice.

Purpose of the Study:

• To systematically review and meta-analyze existing studies.
• To evaluate the association between prenatal exposure to antipsychotic agents and the risk of congenital malformations.
• To provide evidence-based insights for healthcare providers and expectant mothers.

Main Methods:

• Systematic literature search across major databases.
• Inclusion of observational studies (cohort and case-control) assessing antipsychotic use during pregnancy.
• Meta-analysis to pool risk estimates for congenital malformations.

Main Results:

• The meta-analysis indicated a potential increased risk of certain congenital malformations following prenatal antipsychotic exposure.
• Heterogeneity was observed across studies, necessitating careful interpretation.
• Specific malformation types and antipsychotic classes require further investigation.

Conclusions:

• Prenatal exposure to antipsychotic agents may be associated with an elevated risk of congenital malformations.
• Further research is needed to clarify specific risks and inform clinical guidelines.
• Risk-benefit assessment is essential when considering antipsychotic treatment during pregnancy.